Hovione and Merrion Pharmaceuticals have formed a strategic partnership involving Merrion's patented GIPET absorption-enhancing technology by Hovione clients. Hovione will add its commercial reach and technical expertise to generate new products where the use of absorption enhancement through GIPET is appropriate. Established in 2003, Merrion is a pharmaceutical company primarily engaged in facilitating the development of oral forms (tablets/capsules) of drugs that have suboptimal absorption, many of which can only be given by injection, through the use of Merrion'sproprietary drug-delivery technology platform

Hovione and Merrion Pharmaceuticals already had established a cooperative relationship on technical issues relating to GIPET manufacture, and the agreement provides for the companies to collaborate on the feasibility assessment of GIPET with development compounds introduced by third parties. Subject to a decision to proceed, separate technology and manufacturing agreements may be negotiated with the third party. In this way, Hovione will leverage its expertise and manufacturing capability to supply new products from clinical trials to commercialization. In its turn ,Merrion Pharmaceuticals is positioned to add to its current licenses with external development and marketing partners

Source: Hovione